{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T03:30:46Z","timestamp":1786505446671,"version":"build-2736575974"},"reference-count":49,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Bruton's tyrosine kinase inhibitors (BTKi) are widely used in B\u2010cell malignancies. Ibrutinib is associated with atrial fibrillation (AF), but comparative real\u2010world evidence on AF risk across BTKi remains limited. We conducted a nationwide new\u2010user population study using the French national health insurance database (2015\u20132024). Adults initiating ibrutinib, acalabrutinib, zanubrutinib or venetoclax were included, excluding those with prior AF or non\u2010overlapping BTKi indications. The primary outcome was AF requiring hospitalization. Hazard ratios (HRs) were estimated using Cox models with inverse probability of treatment weighting (IPTW). Among 26\u2009393 patients, median follow\u2010up ranged from 167\u2009days in the zanubrutinib cohort to 526\u2009days in the ibrutinib cohort. One\u2010year incidence of hospitalized AF was highest with ibrutinib (2.3%) versus acalabrutinib (0.9%), zanubrutinib (0.7%) and venetoclax (0.5%). Ibrutinib was associated with a significantly higher AF risk versus acalabrutinib (HR 3.03, 95% confidence interval [CI] 1.84\u20135.00), zanubrutinib (HR 7.58, 95% CI 2.05\u201328.06) and venetoclax (HR 9.04, 95% CI 5.81\u201314.04). No significant differences in AF risk were observed between second\u2010generation BTKi and venetoclax. Ibrutinib was associated with a substantially higher risk of hospitalized AF than second\u2010generation BTKi, supporting closer cardiac monitoring in ibrutinib\u2010treated patients.<\/jats:p>","DOI":"10.1111\/bjh.70634","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:40:13Z","timestamp":1782229213000},"page":"534-543","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative atrial fibrillation risk across Bruton's tyrosine kinase inhibitors in B\u2010cell malignancies: A nationwide population\u2010based study"],"prefix":"10.1111","volume":"209","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6289-2567","authenticated-orcid":false,"given":"Yoann","family":"Zelmat","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Toulouse, CHU de Toulouse, Service de Pharmacologie  Toulouse France"},{"name":"Institut des Maladies Cardiovasculaires et m\u00e9tabolique (I2MC), UMR 1297, Universit\u00e9 de Toulouse, INSERM  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4102-7261","authenticated-orcid":false,"given":"Loic","family":"Ysebaert","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Toulouse, CHU de Toulouse, Institut Universitaire du Cancer de Toulouse \u2013 Oncop\u00f4le, Service d'h\u00e9matologie  Toulouse France"},{"name":"Centre de Recherche Contre le Cancer (CRCT), UMR1037, INSERM  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9934-8432","authenticated-orcid":false,"given":"Paul","family":"Gautier","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Toulouse, CHU de Toulouse, Service de Cardiologie  Toulouse France"},{"name":"Centre d'investigation Clinique CIC1436, CHU de Toulouse, Universit\u00e9 de Toulouse, INSERM  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7980-5650","authenticated-orcid":false,"given":"Agnes","family":"Sommet","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Toulouse, CHU de Toulouse, Service de Pharmacologie  Toulouse France"},{"name":"Centre d'investigation Clinique CIC1436, CHU de Toulouse, Universit\u00e9 de Toulouse, INSERM  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6010-2891","authenticated-orcid":false,"given":"Margaux","family":"Lafaurie","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Toulouse, CHU de Toulouse, Service de Pharmacologie  Toulouse France"},{"name":"Centre d'investigation Clinique CIC1436, CHU de Toulouse, Universit\u00e9 de Toulouse, INSERM  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3116-9963","authenticated-orcid":false,"given":"Fabien","family":"Despas","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Toulouse, CHU de Toulouse, Service de Pharmacologie  Toulouse France"},{"name":"Institut des Maladies Cardiovasculaires et m\u00e9tabolique (I2MC), UMR 1297, Universit\u00e9 de Toulouse, INSERM  Toulouse France"},{"name":"Universit\u00e9 de Toulouse, CHU de Toulouse, Institut Universitaire du Cancer de Toulouse \u2013 Oncop\u00f4le, Service d'h\u00e9matologie  Toulouse France"},{"name":"Centre d'investigation Clinique CIC1436, CHU de Toulouse, Universit\u00e9 de Toulouse, INSERM  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024028205"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.07.056"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104428"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024667"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2023.11.014"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211582"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03355"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(20)30262\u20102"},{"key":"e_1_2_12_11_1","unstructured":"AzvolinskyA.Five\u2010Year Results of SEQUOIA Trial Show Maintenance of Benefit for Patients With Del(17p) Treatment\u2010Na\u00efve CLL Treated With Zanubrutinib."},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200006"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010024\u201005859\u2010w"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2327507"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.995522"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2021.10.011"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010024\u201002413\u20105"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40959\u2010024\u201000237\u2010x"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010024\u201005921\u20107"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164\u2010025\u201000619\u20106"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4233"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12214"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2014.11.009"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2023.01.009"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2024.05.003"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.4097\/kja.23278"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.2825"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.4097\/kja.19183"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arthro.2021.06.037"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5753"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfab158"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.70009"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.7326\/M16\u20102607"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj\u20102023\u2010076365"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1999.10474144"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012157"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1360266"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/1740774511420743"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000473"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.06.016"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0018"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae176"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.630942"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.049210"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/cai2.70004"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2905201"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11936\u2010024\u201001067\u2010x"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201015\u20101965"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535\u20107163.MCT\u201019\u20100135"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34787"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70634","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.70634","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70634","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T03:14:00Z","timestamp":1786504440000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.70634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1111\/bjh.70634"],"URL":"https:\/\/doi.org\/10.1111\/bjh.70634","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"2026-04-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}